<prompt> Vismodegib is approved for treatment inBasal cell carcinomaSquamous cell carcinomaMelanomaSkin metastasis of adenocarcinoma  <response>: Mutations in Hh genes encoding the tumor-suppressor patched homolog 1 PTCH1 and smoothened homolog 5MO occur in BCC. Aberrant PTCH1 signaling is propagated by the nuclear transcription factors Gli1 and Gli2 which are salient in the development of BCC and have led to the FDA approval of an oral SMO inhibitor, Vismodegib, to treat advanced inoperable or metastatic BCC Vismodegib trade name Erivedge erIvedZ ERR-i-vej is a drug for the treatment of basal-cell carcinoma BCC. The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration FDA approval Mechanism of action: Vismodegib Erivedge is the first-in-class, oral small molecule inhibitor of the Hedgehog Hh pathway, abnormal activation of which is associated with basal cell carcinoma BCC. Primary and secondary resistance to vismodegib has been documented, albeit at a low rate compared with some other targeted therapies Reference: Harrison Textbook of internal medicine; 19th edition pg 1234. 